Similar companies
Income Statement (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 594M | 0.2% |
| Gross Profit | 523M | 6.7% |
| Cost of Revenue | 71M | 30.9% |
| Operating expense | 505M | 15.2% |
| Net Income | -57M | 31.4% |
| EBITDA | 18M | 112.8% |
Balance Sheet (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 4.21B | 2% |
| Total Liabilities | 4.1B | 1.8% |
| Total Equity | 115M | 72.1% |
| Shares Outstanding | 130M | 0.8% |
Cash Flow (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -118M | 25% |
| Cash from financing | 44M | 42.2% |
EPS
Financial Highlights for Alnylam Pharmaceuticals in Q1 '25
Alnylam Pharmaceuticals reported a revenue of 594M, which is a 0.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 523M, marking a 6.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 71M, a -30.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 505M, showing a -15.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -57M, showing a 31.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 18M, showing a 112.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Alnylam Pharmaceuticals with growth in revenue, gross profit, and net income.
